ADMEchip.com

Four processes, one question

Absorption, distribution, metabolism and excretion describe what the body does to a compound, and exposure decides whether a dose reaches its target and how long it stays. Regulators expect the in vitro part of that answer before anyone is dosed: ICH M12, adopted in May 2024 and issued by the FDA as final guidance that August, sets out how a drug is tested against the main cytochrome P450 enzymes and the transporters that carry drugs across gut, liver and kidney cells.1 Transporters can be "major determinants of the pharmacokinetic, safety and efficacy profiles of drugs", as an international consortium put it in 2010.2

The bench assays an ADME chip builds on

Three assays carry most in vitro ADME work. Caco-2 monolayers, characterised as an intestinal permeability model in 1989,3 remain the permeability standard; ICH M9 accepts Caco-2 data while noting that the line can lack some efflux and uptake transporters.4 Microsomal stability estimates intrinsic clearance from liver microsomes; a 1999 study of 29 drugs found the in vitro half-life approach predicts human clearance best when binding to blood and microsomes is included.5 Hepatocyte assays add uptake and induction; M12 asks for induction data from hepatocytes of at least three donors.1 An ADME chip keeps these cell types, puts them under flow behind a polarised barrier, and connects them.

Gut, liver and kidney, linked by flow

A 2015 four-organ chip kept intestine, liver, skin and kidney equivalents in co-culture for 28 days on a pumped circuit and called itself the first system for "in vitro microfluidic ADME profiling".6 A 2017 gut-liver platform coupled the two tissues in continuous flow and, with a mechanistic model, extracted permeability and metabolic clearance for each.7 In 2020, fluidically coupled gut, liver and kidney chips, scaled computationally, predicted human pharmacokinetic parameters for an orally dosed compound: first-pass absorption, metabolism and excretion on chip.8 A review that year by pharmaceutical-industry scientists concluded that single-organ systems suit tissue-specific questions, while questions linking pharmacokinetics to efficacy or toxicity need inter-linked systems.9

Enzymes and transporters on chip

A chip is only useful for ADME if its cells keep the machinery the guidelines ask about. A duodenum chip built from organoids showed in vivo-like expression, localisation and function of major intestinal drug transporters and, against Caco-2, stronger CYP3A4 expression and induction.10 A proximal tubule chip under physiological shear reported P-gp efflux activity closer to in vivo than static culture,11 and a 3D microfluidic tubule expressed OAT1, OCT2, P-gp and MRP2/4 for transporter-interaction screening.12 The FDA's 2025 roadmap likewise describes a perfused liver chip "displaying liver-like metabolism".13

From chip readouts to PBPK

Physiologically based pharmacokinetic (PBPK) models, which the FDA roadmap defines as "mathematical simulations of drug ADME",13 have reporting guidance from the FDA (2018) and the EMA (in effect since 2019).1415 A 2018 review argued that linked, vascularised organ chips can supply the organ-specific uptake, transport and metabolism inputs PBPK models have lacked, tightening in-vitro-to-in-vivo extrapolation.16 That software layer sits naturally beside the hardware under one name.

The regulatory context

United States law changed in December 2022. The FDA Modernization Act 2.0 replaced "preclinical tests (including tests on animals)" in the Federal Food, Drug, and Cosmetic Act with "nonclinical tests", defined to include "organ chips and microphysiological systems" alongside cell-based assays, computer modeling and animal tests.17 The FDA's April 2025 roadmap plans to reduce animal use in preclinical safety studies with validated new approach methodologies such as organ-on-a-chip systems, starting with monoclonal antibodies,13 and its ISTAND program can qualify tissue chips as drug development tools.18 A May 2025 GAO assessment is the counterweight: organ chips "cannot replace animal testing but may be used alongside animals", and the next generation is "body-on-a-chip" systems linking intestine, liver and kidney.19 The NIH tissue-chip program pursues the same integrated goal.20 In Europe, the EMA is revising its 3Rs guideline; the October 2023 concept paper says knowledge of microphysiological systems "including organ-on-chip models" has "significantly evolved" and plans acceptance criteria for specific contexts of use.21 The OECD's 2018 GIVIMP guidance sets good practice for in vitro methods used in regulatory safety assessment.22

Who builds around the name

• Organ-chip and microphysiological-system developers with a multi-organ or first-pass platform.8
• Contract research organisations offering ADME-Tox and DMPK services on human tissue models, a named category of nonclinical test in United States law.17
• Pharma and biotech DMPK groups following industry recommendations for MPS in ADME work.9
• Vendors of Caco-2 systems, microsomes, hepatocytes and transporter-expressing cells.1
• PBPK and modelling teams turning chip readouts into predicted human exposure.16

ADME chip, ADME-on-a-chip, ADME microphysiological system

Journals write "microphysiological systems for ADME-related applications"9 or "in vitro microfluidic ADME profiling".6 The statute says "organ chips and microphysiological systems";17 NIH says tissue chips;20 the EMA says organ-on-chip.21 Said aloud, all of it shortens to ADME chip, the form this domain holds. ADMET adds toxicity; that sibling name is noted in the offer section.

1. ICH M12: Drug Interaction Studies (adopted 21 May 2024).International Council for Harmonisation; FDA final guidance, August 2024
2. Membrane transporters in drug development.International Transporter Consortium, Nature Reviews Drug Discovery, 2010
3. Hidalgo IJ et al. Characterization of the Caco-2 cell line as a model system for intestinal epithelial permeability.Gastroenterology, 1989
4. ICH M9: Biopharmaceutics Classification System-Based Biowaivers (adopted 20 November 2019).International Council for Harmonisation
5. Obach RS. Prediction of human clearance of twenty-nine drugs from hepatic microsomal intrinsic clearance data.Drug Metabolism and Disposition, 1999
6. Maschmeyer I et al. A four-organ-chip for interconnected long-term co-culture of human intestine, liver, skin and kidney equivalents.Lab on a Chip, 2015
7. Tsamandouras N et al. Integrated gut and liver microphysiological systems for quantitative in vitro pharmacokinetic studies.The AAPS Journal, 2017
8. Herland A et al. Quantitative prediction of human pharmacokinetic responses to drugs via fluidically coupled vascularized organ chips.Nature Biomedical Engineering, 2020
9. Fowler S et al. Microphysiological systems for ADME-related applications: current status and recommendations.Lab on a Chip, 2020
10. Kasendra M et al. Duodenum Intestine-Chip for preclinical drug assessment in a human relevant model.eLife, 2020
11. Jang KJ et al. Human kidney proximal tubule-on-a-chip for drug transport and nephrotoxicity assessment.Integrative Biology, 2013
12. Vriend J et al. Screening of drug-transporter interactions in a 3D microfluidic renal proximal tubule on a chip.The AAPS Journal, 2018
13. Roadmap to Reducing Animal Testing in Preclinical Safety Studies.U.S. Food and Drug Administration, April 2025
14. Physiologically Based Pharmacokinetic Analyses: Format and Content.U.S. Food and Drug Administration guidance, September 2018
15. Guideline on the reporting of PBPK modelling and simulation (EMA/CHMP/458101/2016).European Medicines Agency, effective July 2019
16. Prantil-Baun R et al. Physiologically based pharmacokinetic and pharmacodynamic analysis enabled by microfluidically linked organs-on-chips.Annual Review of Pharmacology and Toxicology, 2018
17. Public Law 117-328, Section 3209, Animal testing alternatives (the FDA Modernization Act 2.0).Approved 29 December 2022; 136 Stat. 5821-5822
18. Innovative Science and Technology Approaches for New Drugs (ISTAND) Program.U.S. Food and Drug Administration
19. Human Organ-on-a-Chip (Technology Assessment GAO-25-107335).U.S. Government Accountability Office, May 2025
20. Tissue Chip for Drug Screening.NIH National Center for Advancing Translational Sciences
21. Concept paper on the revision of the guideline on regulatory acceptance of 3Rs testing approaches (EMA/CHMP/CVMP/452614/2023).European Medicines Agency, October 2023
22. Guidance Document on Good In Vitro Method Practices (GIVIMP).OECD Series on Testing and Assessment No. 286, 2018